Showing 20 of 24 recruiting trials for “Graft versus host disease”
Electrostimulation Study for Ocular Graft vs. Host Disease
👨⚕️ Zhonghui Luo, MD, PhD, Massachusetts Eye and Ear Infirmary📍 1 site📅 Started Nov 2025View details ↗
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
👨⚕️ Xiaoyu Zhu, Ph.D, The First Affiliated Hospital of USTC📍 1 site📅 Started Jul 2025View details ↗
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.
👨⚕️ Ting Yang, MD, PhD, First Affiliated Hospital of Fujian Medical University📍 1 site📅 Started May 2025View details ↗
RecruitingNCT07314892 ↗
Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).
👨⚕️ Jan Puchowski, MD, Department of Hematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland📍 1 site📅 Started Apr 2025View details ↗
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
👨⚕️ Ramzi Abboud, M.D., Washington University School of Medicine📍 1 site📅 Started May 2024View details ↗
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
RecruitingNCT05718791 ↗
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
👨⚕️ Christina Dieli-Conwright, Dana-Farber Cancer Institute📍 2 sites📅 Started Apr 2022View details ↗
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
RecruitingNCT04700657 ↗
The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
RecruitingNCT04660487 ↗
Relationship Between "FODMAPs" and "GVHD"
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →